Clarification on the use of neurological imunotherapy during the COVID-19 pandemic: consensus, where it exists, and the remaining uncertainties

neurodiem-image

Abstract

The coronavirus disease 2019 (COVID-19) pandemic is concerning for patients with neuroimmunological diseases who are receiving immunotherapy. Uncertainty remains about whether immunotherapies increase the risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or increase the risk of severe disease and death upon infection. National and international societies have developed guidelines and statements, but consensus does not exist in several areas.

Möchten Sie mehr lesen?

Loggen Sie sich ein oder registrieren Sie sich, um Zugang zu allen Inhalten von Neurodiem zu erhalten.

Sie haben bereits einen Account? Einloggen

© Springer Nature Limited 2020